Across 2 decades following the marketing of immunoglobulin, no new safety concerns appeared in pediatric adverse event ...
The disease is posing a risk in several countries where a high number of cases were reported, with confirmed human cases, ...
A high number of cases were reported in the last 12 months - with a 5-fold increase in some areas - and 143 deaths ...
Cenrifki prevents MS disease progression and Itvisma delivers a healthy gene-to-cell nuclei, addressing the root cause of SMA.
X-linked hypophosphataemia (XLH) is the most prevalent heritable form of rickets in children and of osteomalacia in adults. Until a few years ago, standard treatment consisted of oral phosphate salts ...
Minjuvi® (tafasitamab), in combination with rituximab and lenalidomide, is the first and only chemotherapy-free CD19 and CD20 ...
Ziftomenib was approved by the U.S. Food and Drug Administration (FDA) in November 2025 for the treatment of adult patients with R/R NPM1 -m AML who have no satisfactory alternative treatment options, ...
Abogen, a clinical-stage biotechnology company focused on RNA innovation, today announced preliminary clinical results from the first-in-human (FIH) study of ABO2203 in patients with ...
NEW YORK, April 22, 2026 (GLOBE NEWSWIRE) -- TG Therapeutics, Inc. (NASDAQ: TGTX), today announced the presentation of data highlighting BRIUMVI ® (ublituximab-xiiy) in patients with relapsing forms ...
New treatment option for rare, life-altering pediatric brain tumors Less than 10% of new medicine approvals over the past ...
Treatment with spesolimab led to rapid clinical improvement in patients with generalized pustular psoriasis and showed a favorable safety profile.
(NYSE: PFE) announced that the U.S. Food and Drug Administration (FDA) accepted for Priority Review a supplemental Biologics License Application (sBLA) for perioperative (before and after surgery) ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results